Akari Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -15,253 | -4,490 | -7,367 | -1,845 |
EBIT | -3,119 | |||
Net Income | -14,455 | -5,298 | -6,400 | -1,895 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -2,488 | -3,038 | -2,101 | -3,256 |
Cash | 2,768 | 5,203 | 2,484 | 2,711 |
Basic Shares | 21 | 21 | 16 | 15 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -13 | -4 | -3 | |
EBITDA | -17,352 | -19,533 | -10,004 | -17,744 |
EBIT | -19,547 | -10,008 | -17,748 | |
Net Income | -17,298 | -19,791 | -10,008 | -17,748 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,568 | -12,552 | -16,432 | -21,504 |
Cash | 5,203 | 2,599 | 3,845 | 13,250 |
Basic Shares | 21 | 5 | 2 | 1 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$9.72 |
2025-09-30 | -$0.20 |
2025-06-30 | -$0.06 |
2025-03-31 | -$0.19 |